Yearly Archives: 2023

Our review entitled ” High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer” (Bottger et al.,  J Exp Clin Cancer Res. 2021 Oct 30;40(1):343) is getting attention. Not only in PubMed but now also via a Podcast in the series Decoding Health Care Research.   Watch on youtube: https://youtu.be/eDUWWOkY4S0?si=8O8Ffxrw8PEdnXW6  

Celebration of next generation mass spectrometry in the Proteomics Core Facility  Venue:            Auditorium O2 building Date:               14.00- 17.30, 23 Jan. 2023   Program 14.00- 14.15    Inloop (koffie / thee)   14.15-14.20     Welcome (Connie Jimenez, director Proteomics Core Resource) 14.20-14.30     (Phospho)proteomics highlights of the past decade (Connie)   Collaborator orals 14.30-14.45     Proteomics to study […]

Core question: Can we identify predictive protein biomarkers for the selection of patients benefiting from  platinum-based adjuvant chemotherapy (ACT) in non-small cell lung cancer (NSCLC)? Core insight: Our study published Nov 27th in Molecular Oncology presents the discovery of predictive biomarkers that can aid in distinguishing patients with NSCLC likely to derive clinical benefit from […]

In our recent study pubished in Cell Reports, PhD student Andrea Valles shows how profile-guided phosphoproteomics can be used to select low dose combination treatment based on three kinase inhibitors. Kinase activity ranking of individual cell lines using our INKA pipeline, provided the rationale for a combination of within pathway and parallel pathway targeting with triple  […]

Connie Jimenez, The Netherlands   What is your current position and location? I am full Professor of Translational OncoProteomics, Principle Investigator of the OncoProteomics Laboratory and Director of the Proteomics Core Resource, all at Amsterdam University Medical Center, in the beautiful city Amsterdam where I was born, in The Netherlands. How did you get started […]

Can mass spectrometry-based phosphoproteomics help understand the (lack of) response to EGFR-blockade and identify predictive markers and new treatment options? We analyzed a unique collection of 29 molecularly characterized colorectal patient-derived xenograft (PDX) tumors, annotated for cetuximab response. Proteomics identified CXADR as promising marker of treatment response, while phosphoproteomics coupled to single sample kinase activity […]

In the beautiful academiegebouw in Utrecht, Valentina did an excellent job defending her thesis in front of a multi-disciplinary committee including clinicians, a biochemist and cancer biologist.

This news article highlights the study of Iris Glycofrydis published in Molecular and Cellular Proteomics last year. It aimed to uncover the functions of the tumor suppressor Foliculin that plays a role in renal cancer (DOI:10.1016/j.mcpro.2022.100263 ). NB On Nov 22, 2022 she defended her thesis including this study in an excellent manner! See page […]

Photo impression of a great day that started with a seminar entitled “Phosphoproteomics approaches to rationalise anticancer drug responses: towards next generation precision medicine ” by Prof. Pedro Cutillas of the Barts Cancer Institute in London, followed by the thesis defense ceremony. Carolien did a good job defending her thesis. Together copromotor Jacqueline Cloos and […]